The multivalent nature of PAT-SM6 would therefore permit this antibody to bind LDL and GRP78 simultaneously, consistent with a mechanism where PAT-SM6 binds plasma LDL and targets tumour cells by binding to GRP78 which is over-expressed externally on the cell surface of tumour cells [3]. This evidence concerns the gene HSPA5 and neoplasm.